Clinical Trials Browser

Active not recruiting × Ipilimumab × Myeloid × Clear all

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes